I want to ...

Clinical Trials


In cancer research, a clinical trial is an organized study conducted among people with cancer to answer specific questions about a new treatment or new way of using a known treatment.

Each study tries to increase medical knowledge and find new and better ways to help cancer patients.

The decision to participate in a clinical trial is an important one.

The National Institutes of Health provides information on its website to help guide patients in their decision.

Besides studying new anticancer drugs, clinical trials study new combinations of drugs already used in cancer treatment, new ways of providing treatment and how lifestyle changes can help cancer patients or prevent cancer from occurring.

Other trials compare the best known standard therapy with a newer therapy to see if one produces more cures and causes fewer side effects than the other.

Through our partnership with Eastern Maine Medical Center, the Harold Alfond Center for Cancer Care offers patients access to many of the same cutting-edge research studies and experimental medications that are used at the top cancer centers throughout the country.

The following clinical trials (unless indicated as closed) are open to enrollment.

More information about each trial can be found at the National Cancer Institute's website.

For more information about MaineGeneral's ongoing clinical trials, please call (207) 626-4855 or (207) 626-4806.

Trials by Site Number Protocol Name


Breast- Adjuvant NSABP B-47

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node Positive or High Risk Node Negative HER2-Low Invasive Breast Cancer



A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative HER2-Negative Breast Cancer


SWOG S1007

A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes Hormone Receptor Positive and HER2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less



A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2 Positive Ductal Carcinoma In Situ Resected by Lumpectomy


Colorectal-Adjuvant CIRB
CALGB C80702

A Phase III Trial of 6 vs. 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer


Gastric/Gastroesophageal SWOG S1201

A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer



Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in Patients With Metastatic Pancreatic Cancer After Prior Chemotherapy


Glioblastoma NCCTG N0872

Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma



Chemotherapy Toxicity in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer


Leukemia-AML CALGB 11001

A Phase II Study Incorporating Sorafenib (IND# 69896, NSC# 724772) Into the Therapy of Patients > 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia


ECOG E2906

Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly Diagnosed Acute Myeloid Leukemia in Older Adults (Age Equal to or Greater Than 60 Years)


CALGB 10701

A Phase II Study of Dasatinib (Sprycel) (IND# 73969, NSC# 732517) as Primary Therapy Followed by Transplantation for Adults Greater Than or Equal to 50 Years With Newly Diagnosed PH+ Acute Lymphoblastic Leukemia by CALGB, ECOG, SWOG and NCIC CTG


SWOG S1117

A Randomized Phase II Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)


Lung Cancer CIRB

A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>4 cm)-IIIA Non-Small Cell Lung Cancer (NSCLC)


CALGB 30801

A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer



Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC


Lymphoma CALGB 50904

A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC# 681239, IND# 58443) and Bendamustine in Patients With Untreated Follicular Lymphoma


ECOG E1411

Intergroup Randomized Phase II Four Arm Study in Patients >60 with Previously Untreated Mantle Cell Lymphoma of Therapy With: Arm A = Rituximab + Bendamustine Followed by Rituximab Consolidation (RB→R); Arm B = Rituximab + Bendamustine + Bortezomib Followed by Rituximab Consolidation (RBV→R); Arm C = Rituximab + Bendamustine Followed by Lenalidomide + Rituximab Consolidation (RB→LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed by Lenalidomide + Rituximab Consolidation (RBV→LR)


Melanoma CIRB ECOG E1609

A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy vs High Dose Interferon a-2b for Resected High Risk Melanoma


Other Studies

Randomized Phase II Pilot Study of Loratadine for the Prevention of Pain Caused by the Granulocyte Colony Stimulating Factor Pegfilgrastim


Prevention NSABP

Statin Polyp Prevention Trial in Patients with Resected Colon Cancer


Renal Cell CIRB SWOG S0931

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study


CALGB 90601

A Randomized Double Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma


Supportive Care Young &

An Education and Supportive Care Intervention Study for Young Women with Breast Cancer
For newly diagnosed women age 45 and younger

Helpful Resources